Comparative analysis on seroprevalence of hepatitis B in 2010 and 2020 in Jiangsu Province

JIANG Jie; QIAN Jiao; ZHU Li-guo; YAO Min-fang; ZHU Tao; XU Jian-fang; CAO Min-quan; PENG Hong; ZHU Feng-cai; ZHAI Xiang-jun

doi:10.16462/j.cnki.zhjbkz.2023.02.018

Volume 27 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(2): 238-243

JIANG Jie, QIAN Jiao, ZHU Li-guo, YAO Min-fang, ZHU Tao, XU Jian-fang, CAO Min-quan, PENG Hong, ZHU Feng-cai, ZHAI Xiang-jun. Comparative analysis on seroprevalence of hepatitis B in 2010 and 2020 in Jiangsu Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(2): 238-243. doi: 10.16462/j.cnki.zhjbkz.2023.02.018

Citation:

JIANG Jie, QIAN Jiao, ZHU Li-guo, YAO Min-fang, ZHU Tao, XU Jian-fang, CAO Min-quan, PENG Hong, ZHU Feng-cai, ZHAI Xiang-jun. Comparative analysis on seroprevalence of hepatitis B in 2010 and 2020 in Jiangsu Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(2): 238-243. doi: 10.16462/j.cnki.zhjbkz.2023.02.018

Citation:

JIANG Jie, QIAN Jiao, ZHU Li-guo, YAO Min-fang, ZHU Tao, XU Jian-fang, CAO Min-quan, PENG Hong, ZHU Feng-cai, ZHAI Xiang-jun. Comparative analysis on seroprevalence of hepatitis B in 2010 and 2020 in Jiangsu Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(2): 238-243. doi: 10.16462/j.cnki.zhjbkz.2023.02.018

PDF( 1646 KB)

Comparative analysis on seroprevalence of hepatitis B in 2010 and 2020 in Jiangsu Province

doi: 10.16462/j.cnki.zhjbkz.2023.02.018

1.
Major Project Executive Office, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
2.
Director Office, Zhangjiagang County Center for Disease Control and Prevention, Zhangjiagang 215600, China
3.
Director Office, Danyang County Center for Disease Control and Prevention, Danyang 212310, China
4.
Major Project Executive Office, Taixing County Center for Disease Control and Prevention, Taixing 225400, China
5.
Key Laboratory of Intestinal Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China

JIANG Jie and QIAN Jiao contributed equally to this article

Funds:

National Major Science and Technology Projects 2018ZX10715-002

More Information

Corresponding author: ZHAI Xiang-jun, E-mail: jszxj@jscdc.cn
Received Date: 2021-12-21
Rev Recd Date: 2022-05-05

Available Online: 2023-02-20

Publish Date: 2023-02-10

Abstract

Abstract

Objective To describe the characteristics of epidemic change of hepatitis B and to analyze the effect of comprehensive prevention and control measures for hepatitis B in Jiangsu Province. Methods According to the method of a cross-sectional survey, two large-scale seroepidemiological surveys of hepatitis B were carried out in 2010 and 2020 in Zhangjiagang City, Danyang City and Taixing City. Results A total of 148 196 and 100 989 people were investigated in 2010 and 2020, respectively. Age-standardHBsAgprevalence was 7.36% in 2010 and 5.33% in 2020, with a decrease by 28.55%. The HBsAg standard positive rates in Zhangjiagang City, Danyang City and Taixing City demonstration areas in 2020 were 2.92%, 5.25% and 7.14%, respectively, which were significantly lower than the HBsAg levels in 2010. According to the comparison of different age groups, the HBsAg positive rate decreased from 2020 to 2010 in all age groups, especially in the 20-35 age group. In the 2020 survey, the HBsAg positive rate was 4.88% in the population with a history of hepatitis B vaccination, which was significantly lower than that in the unvaccinated population (P < 0.001). The overall positive rate of anti-HBs was 45.55% in the 2020 survey, which was highest in infants aged 1- < 5 years, and decreased significantly in adolescents aged 5- < 20 years. Conclusion Through the implementation of the comprehensive prevention and control strategy for hepatitis B, the prevention and control of hepatitis B in the Jiangsu Province has achieved remarkable results, but the adult hepatitis B vaccination still needs to be strengthened.
- Hepatitis B,
- Serological survey,
- Immunization strategy,
- Hepatitis B vaccine

FullText(HTML)

References(19)

References

[1]	WHO. Global hepatitis report, 2017[EB/OL]. (2017-04-19)[2021-12-21]. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
[2]	WHO. Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. (2016-05-17)[2021-12-21]. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
[3]	Liang XF, Bi SL, Yang WE, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination[J]. Vaccine, 2013, 31(Suppl 9): J21-J28. DOI: 10.1016/j.vaccine.2013.08.012.
[4]	Cui FQ, Shen LP, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477.
[5]	Liu J, Liang WN, Jing WE, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[6]	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B(2019 version)[J]. Journal of Clinical Hepatology, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	李兰娟, 阮冰. 重大传染病规模化现场流行病学和干预研究标准操作规程[M]. 杭州: 浙江大学出版社, 2019: 1. Li L, Ruan B. Large-scale epidemiological and intervention studies of major infectious disease: standard operating procedure[M]. Hangzhou University Press, 2019: 1.
[8]	Yang SG, Ding C, Cui YX, et al. Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study[J]. BMJ Open, 2017, 7(4): e014947. DOI: 10.1136/bmjopen-2016-014947.
[9]	吴疆, 张卫, 韩莉莉, 等. 北京市人群乙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 2007, 28(6): 555-557. DOI: 10.3760/j.issn:0254-6450.2007.06.010. Wu J, Zhang W, Han LL, et al. A sero-epidemiological study on hepatitis Beijing general population in Beijing[J]. Chin J Epidemiol, 2007, 28(6): 555-557. DOI: 10.3760/j.issn:0254-6450.2007.06.010.
[10]	高培, 王怀, 陈维欣, 等. 北京市自然人群乙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 2016, 37(5): 658-662. DOI: 10.3760/cma.j.issn.0254-6450.2016.05.014. Gao P, Wang H, Chen W, et al. A sero-epidemiological study of hepatitis B among general population in Beijing. [J]. Chin J Epidemiol, 2016, 37(5): 658-662. DOI: 10.3760/cma.j.issn.0254-6450.2016.05.014.
[11]	庄辉. 我国乙型肝炎防治现状及目标[J]. 中华内科杂志, 2008, 47(10): 793-795. DOI: 10.3321/j.issn:0578-1426.2008.10.001. Zhuang H. Current status and goals of hepatitis B prevention and treatment[J]. Chin J Intern Med, 2008, 47(10): 793-795. DOI: 10.3321/j.issn:0578-1426.2008.10.001.
[12]	张丽, 徐爱强, 颜丙玉, 等. 山东省1~59岁人群乙型肝炎疫苗接种情况调查分析[J]. 中国疫苗和免疫, 2009, 15(2): 159-162. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM200902025.htm Zhang L, Xu AQ, Yan BY, et al. Analysis on Hepatitis B Vaccine Coverage among the Population of 1~59 Years Old in Shandong Province[J]. Chinese Journal of Vaccines and Immunization, 2009, 15(2): 159-162. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM200902025.htm
[13]	鲁影, 黄勇, 汪慧, 等. 2008年和2018年广州市HBV易感人群的流行病学特征[J]. 中华疾病控制杂志, 2021, 25(3): 341-345. DOI: 10.16462/j.cnki.zhjbkz.2021.03.017. Lu Y, Huang Y, Wang H, et al. Characteristics of population susceptible to hepatitis B infection in Guangzhou, 2008 and 2018[J]. Chin J Dis Control Prev, 2021, 25(3): 341-345. DOI: 10.16462/j.cnki.zhjbkz.2021.03.017.
[14]	国家卫生计划生育委员会, 国家发展改革委, 教育部, 等. 中国病毒性肝炎防治规划(2017-2020年)[J]. 中国病毒病杂志, 2018, 8(1): 1-5. DOI: 10.16505/j.2095-0136.2018.0001. National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, et al. Action plan for the prevention and treatment of viral hepatitis in China (2017-2020)[J]. Chin J Viral Dis, 2018, 8(1): 1-5. DOI: 10.16505/j.2095-0136.2018.0001.
[15]	Mast EE, Weinbaum CM, Fiore AE, et al. Advisory committee on immunization practices (ACIP) centers for disease control and prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part Ⅱ: immunization of adults[J]. MMWR Recomm Rep, 2006, 55(RR-16): 1-33.
[16]	刘中芹, 王晓琼, 张国庆, 等. 乙肝疫苗免疫5年后抗-HBs衰减儿童免疫记忆观察[J]. 中华疾病控制杂志, 2016, 20(3): 315-316, 322. DOI: 10.16462/j.cnki.zhjbkz.2016.03.025. Liu ZQ, Wang XQ, Zhang GQ, et al. The observation of the immunization memory of anti-HBs decay children 5 years after primary immunization with hepatitis B vaccination[J]. Chin J Dis Control Prev, 2016, 20(3): 315-316, 322. DOI: 10.16462/j.cnki.zhjbkz.2016.03.025.
[17]	吴维寿, 孙超美, 姜铭波, 等. 乙型肝炎免疫预防持续效果探讨(18年随访结果)[J]. 中国计划免疫, 2005, 11(3): 204-207. DOI: 10.3969/j.issn.1006-916X.2005.03.010. Wu WS, Sun CM, Jiang MB, et al. Long-term effect of plasma-derived vaccine in the prevention of Hepatitis B (Eighteen Years'Follow-up Study)[J]. Chinese Journal of Vaccines and Immunization, 2005, 11(3): 204-207. DOI: 10.3969/j.issn.1006-916X.2005.03.010.
[18]	龚晓红, 王富珍, 李辉, 等. 北京市儿童乙型肝炎疫苗接种12年后免疫效果观察[J]. 中华预防医学杂志, 2005, 39(4): 265-268. DOI: 10.3760/j:issn:0253-9624.2005.04.011. Gong XH, Wang FZ, Li H, et al. Observation on effects of hepatitis B vaccine immunization for 12 years in children in Beijing[J]. Chin J Prev Med, 2005, 39(4): 265-268. DOI: 10.3760/j:issn:0253-9624.2005.04.011.
[19]	刘蓬勃, 徐慧文. 乙型肝炎疫苗接种若干问题的探讨[J]. 中国公共卫生, 2000, 16(1): 73-74. DOI: 10.3321/j.issn:1001-0580.2000.01.042. Liu PB, Xu HW. Discussion on some problems of hepatitis B vaccine vaccination[J]. Chin J Publ Heal, 2000, 16(1): 73-74. DOI: 10.3321/j.issn:1001-0580.2000.01.042.